AMGN vs BMY
By Alex · Tickerpine
Amgen Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | BMY |
|---|---|---|
| Price | $416.18 | $63.70 |
| Market cap | $225.15B | $130.12B |
| P/E ratio | 25.7 | 14.0 |
| ROE | 91.47% | 46.60% |
| Profit margin | 22.95% | 18.87% |
| Revenue growth | 9.50% | 5.70% |
| Dividend yield | 2.43% | 3.96% |
| Beta | 0.41 | 0.23 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs BMY in plain English
- AMGN is the bigger company — about 1.7× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.0 vs 25.7).
- AMGN earns a higher return on equity (91% vs 47%).
- AMGN is growing revenue faster (10% vs 6%).
- BMY has the higher dividend yield (3.96% vs 2.43%).
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.